- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05887050
Effects of a Dietary Supplement Containing Salacia Extract, Citrus Bioflavonoids, and Trivalent Chromium on Markers of Glucose Control
Effects of a Dietary Supplement Containing Salacia Extract, Citrus Bioflavonoids, and Trivalent Chromium on Markers of Glucose Control and Quality of Life: A Randomized, Placebo-Controlled, Double-Blind Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study was a double-blind, randomized, two-arm, placebo-controlled trial of apparently healthy men and women recruited at a single investigational center in Northeast Ohio (i.e. The Center for Applied Health Sciences).
Subjects will attend four study visits. During Visit 1, subjects will be screened for participation (i.e., medical history, physical exam, routine blood work [also HgA1c, insulin], background baseline diet). Over the next 12 weeks, subjects will attend Visits 2-4, wherein assessments of serum glucose, insulin, HOMA-IR, 2-hour glucose tolerance test (GTT), NMR profile, HgA1c, C-reactive protein, adiponectin, ferritin, waist circumference, quality of life questionnaire, and various visual analog scales for appetite, satiety, and cravings will be made (see Study Schematic for details).
Comprehensive side effect profile/ adverse event monitoring will take place throughout the study duration. The study will be conducted following ICH-GCP guidelines to ensure subject safety and scientific integrity of the data.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Canfield, Ohio, United States, 44406
- The Center for Applied Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Provide voluntary signed and dated informed consent.
- Be in good health as determined by medical history and routine blood chemistries.
- Age between the ages of 21 and 65 (inclusive).
- Body Mass Index of 18.5-34.99 (inclusive).
- Body weight of at least 120 pounds.
- Fasting blood sugar of 100-125 (inclusive) OR HgA1c of 5.7-6.4% (inclusive).
- Normotensive (seated, resting systolic blood pressure <140 mm Hg and diastolic blood pressure < 90 mm Hg. If the first measurement is slightly elevated above these limits, the subject will be given a brief (5 minute) rest period, and two more measurements will be taken. The average of all three measurements will be used to determine eligibility.
- Normal seated, resting heart rate (<90 per minute).
- Willing to duplicate their previous 24-hour diet, refrain from caffeine for 12 hrs and exercise
Exclusion Criteria:
- History of unstable or new-onset cardiovascular or cardiorespiratory disease.
- History of diabetes, or other endocrine disorder.
- Fasting blood sugar of > 125 mg/dL or HgA1c of > 6.4%.
- History of use of medications or dietary supplements known to affect glycemia or insulinemia.
- History of hyperparathyroidism or an untreated thyroid disease.
- History of malignancy in the previous 5 years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin).
- Prior gastrointestinal bypass surgery (Lapband), etc.
- Other known gastrointestinal or metabolic diseases that might impact nutrient absorption or metabolism, e.g. short bowel syndrome, diarrheal illnesses, history of colon resection, gastro paresis, Inborn-Errors-of-Metabolism (such as PKU).
- Chronic inflammatory condition or disease (e.g. rheumatoid arthritis, Crohn's disease, ulcerative colitis, Lupus, HIV/AIDS, etc.).
- Known sensitivity to any ingredient in the test formulations as listed in the Certificates-of-Analysis.
- Currently participating in another research study with an investigational product or have been in another research study in the past 30 days.
- Any other diseases or conditions that, in the opinion of the medical staff, could confound the primary endpoints or place the subject at increased risk of harm if they were to participate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active
Tablet containing 400 mcg chromium (delivered as Crominex® 3+, a blend of chromium, Capros® Amla Extract (Fruit), PrimaVie® Shilajit), and 325 mg of MetaviveTM complex (Salacia Chinensis Extract (Fruit) and a Citrus Bioflavonoid Complex)
|
Blend of chromium, amla fruit extract, and citrus bioflavonoids
|
Placebo Comparator: Placebo
Identical size, shape, and weight maltodextrin tablet
|
Maltodextrin tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glucose kinetics
Time Frame: Change from baseline to 12 weeks.
|
Serum glucose response during a two hour oral sucrose tolerance test.
|
Change from baseline to 12 weeks.
|
Insulin kinetics
Time Frame: Change from baseline to 12 weeks.
|
Serum insulin response during a two hour oral sucrose tolerance test.
|
Change from baseline to 12 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hemoglobin A1c (HgA1c)
Time Frame: Change from baseline to 12 weeks.
|
Serum HgA1c
|
Change from baseline to 12 weeks.
|
C-reactive protein
Time Frame: Change from baseline to 12 weeks.
|
Serum C-reactive protein
|
Change from baseline to 12 weeks.
|
Adiponectin
Time Frame: Change from baseline to 12 weeks.
|
Serum adiponectin
|
Change from baseline to 12 weeks.
|
Ferritin
Time Frame: Change from baseline to 12 weeks.
|
Serum ferritin
|
Change from baseline to 12 weeks.
|
Blood urea nitrogen to creatinine ratio
Time Frame: Change from baseline to 12 weeks.
|
The ratio of blood urea nitrogen to creatinine in serum.
|
Change from baseline to 12 weeks.
|
Appetite
Time Frame: Change from baseline to 12 weeks.
|
Appetite as measured by a 10 cm visual analogue scale, where higher values represent greater appetite.
Values range from 1-10, and a greater appetite score would be a worse outcome in these participants.
|
Change from baseline to 12 weeks.
|
Satiety
Time Frame: Change from baseline to 12 weeks.
|
Satiety as measured by a 10 cm visual analogue scale, where higher values represent greater satiety.
Values range from 1-10, and a greater satiety score would be a better outcome in these participants.
|
Change from baseline to 12 weeks.
|
Food cravings
Time Frame: Change from baseline to 12 weeks.
|
Food cravings as measured by a 10 cm visual analogue scale, where higher values represent greater food cravings.
Values range from 1-10, and a greater food cravings score would be a worse outcome in these participants.
|
Change from baseline to 12 weeks.
|
Sweet food cravings
Time Frame: Change from baseline to 12 weeks.
|
Sweet food cravings as measured by a 10 cm visual analogue scale, where higher values represent greater sweet food cravings.
Values range from 1-10, and a greater sweet food cravings score would be a worse outcome in these participants.
|
Change from baseline to 12 weeks.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MEND-2023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glucose Intolerance
-
Yonsei UniversityNot yet recruitingType 2 Diabetes | Impaired Glucose Intolerance
-
University of California, IrvineUniversity of California, Davis; University of California, San FranciscoCompletedStress, Psychological | Pregnancy Related | Glucose Intolerance During PregnancyUnited States
-
Arizona State UniversityRecruiting
-
University of SaskatchewanRoyal University Hospital FoundationCompletedGlucose IntoleranceCanada
-
Glycemic Index Laboratories, IncDSM Nutritional Products, Inc.Completed
-
Materia Medica HoldingCompletedImpaired Glucose ToleranceRussian Federation
-
Joslin Diabetes CenterCompleted
-
TakedaCompletedImpaired Glucose ToleranceJapan
-
China Academy of Chinese Medical SciencesUnknownImpaired Glucose Tolerance
-
University of TromsoCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States